The largest holder of Madrigal Pharmaceuticals stock is Baker Bros. Advisors LP, with 2.1 million shares (9.28% of the company), worth about $1.16 billion as of September 25, 2026. The 10 largest holders together own 60.3%.
In Q2 2026, 443 institutional holdings reports listed shares worth $12.70 billion.
Insiders reported 92 transactions in the last two years: 43 sales worth $207.07 million and 2 purchases. The newest one on file is from May 18, 2026 (Soergel David M.D., Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 18, 2026.

2026Q2
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Baker Bros. Advisors LP | 2.1 million | 9.28% | $1.2B |
| RTW Investments LP | 2.0 million | 8.63% | $1.1B |
| Janus Henderson Investors US LLC | 1.9 million | 8.38% | $1.0B |
| Avoro Capital Advisor LLC | 1.8 million | 7.93% | $990.0M |
| Paulson & Co., Inc. | 1.3 million | 5.80% | $724.0M |
| BlackRock Advisors LLC | 1.1 million | 4.92% | $614.0M |
| Rebecca Taub4.797 % | 1.1 million | 4.80% | $598.0M |
| Vanguard Capital Management LLC | 835,668 | 3.62% | $451.0M |
| Wellington Trust Co., NA | 825,714 | 3.57% | $446.0M |
| Vanguard Portfolio Management LLC | 781,731 | 3.38% | $422.0M |
As of September 25, 2026.
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 443 | – | $12.7B |
| Q1 2026 | 411 | 23.8 million | $12.4B |
| Q4 2025 | 421 | 23.6 million | $13.7B |
| Q3 2025 | 387 | 23.4 million | $10.7B |
| Q2 2025 | 338 | 23.7 million | $7.2B |
| Q1 2025 | 353 | 23.7 million | $7.9B |
| Q4 2024 | 323 | 23.0 million | $7.1B |
| Q3 2024 | 291 | 22.8 million | $4.8B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Soergel David M.D. | May 18, 2026 | Officer | Sale at price 515.90 per share. | $435,420 |
| Sibold William John | Mar 6, 2026 | Chief Executive Officer | Sale at price 431.94 per share. | $718,316 |
| Dier Mardi C | Mar 6, 2026 | Chief Financial Officer | Sale at price 425.08 - 437.65 per share. | $853,993 |
| Huntsman Carole A | Mar 6, 2026 | Officer | Sale at price 431.94 per share. | $180,983 |
| Kelley Shannon T | Mar 6, 2026 | General Counsel | Sale at price 431.94 per share. | $155,498 |
| Taub Rebecca M.D. | Mar 6, 2026 | Director | Sale at price 431.94 per share. | $212,083 |
| Soergel David M.D. | Mar 4, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Huntsman Carole A | Mar 4, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Kelley Shannon T | Mar 4, 2026 | General Counsel | Stock Award(Grant) at price 0.00 per share. | – |
| Sibold William John | Mar 4, 2026 | Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Dier Mardi C | Mar 4, 2026 | Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Dier Mardi C | Mar 2, 2026 | Chief Financial Officer | Sale at price 427.21 per share. | $505,389 |
Newest 12 of 92 insider transactions in the last two years.
Baker Bros. Advisors LP, with 9.28% of the company (as of September 25, 2026). Next: RTW Investments LP (8.63%) and Janus Henderson Investors US LLC (8.38%).
443 institutional holdings reports listed Madrigal Pharmaceuticals shares in Q2 2026 worth $12.70 billion.
In the last two years insiders reported 43 sales and 2 purchases (92 transactions in all); the newest on file is from May 18, 2026.